In Q3 2024, Perceptive Advisors held 89 positions worth $4.5B. They initiated 11 new positions and exited 51. Their largest holding was ACLX ($324.7M). Portfolio value grew +13.4% versus the prior quarter.
Frequently asked questions
What stocks did Perceptive Advisors own in Q3 2024?
Perceptive Advisors held 89 biotech stocks in their 13F portfolio in Q3 2024. Their top positions include ACLX, NUVL, FOLD, IOVA, PCVX. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Perceptive Advisors's portfolio worth in Q3 2024?
Perceptive Advisors's tracked biotech portfolio was worth $4.5B across 89 positions, with total assets under management of approximately $8B. Portfolio values are based on 13F filings with the SEC.
What did Perceptive Advisors buy in Q3 2024?
Perceptive Advisors initiated 11 new positions in Q3 2024, including PODD, ORKA, DYN, ADGM, TIL and 6 more. They also increased 24 existing positions.
What did Perceptive Advisors sell in Q3 2024?
Perceptive Advisors fully exited 51 positions in Q3 2024, including CYTK, CBAY, ASND, NAMSW, MLTX and 46 more. They also trimmed 22 existing positions.
Is Perceptive Advisors a biotech fund?
Clinical-stage biotech specialist known for deep scientific due diligence and concentrated bets on binary catalysts like FDA approvals and pivotal trial readouts. Edelman and team leverage decades of pattern recognition in drug development to identify asymmetric risk/reward setups.
Want AI analysis, insider signals, and catalyst overlays for Perceptive Advisors?
View latest Perceptive Advisors portfolio →